

Two leading US microbiology labs present interim evaluation data on webinar

Q-linea AB (publ) (OMX:QLINEA) announces webinar titled “Clinical Evaluation of an FDA-Cleared High-Throughput Rapid Antibiotic Susceptibility Testing System” hosted 360Dx.

This week, Q-linea partnered with 360Dx to host a webinar that is now available for playback on demand [here](#). The webinar featured Dr. Elizabeth Garrett of Penn State College of Medicine and Dr. Rebecca Yee of George Washington University discussing interim results from their respective evaluations of the ASTar system. These microbiology labs each receive between 15,000 and 30,000 blood cultures annually.

In both laboratories, the ASTar produced minimum inhibitory concentration (MIC) results approximately 36 hours faster than the standard of care instruments, providing opportunities for earlier interventions by clinicians to optimize antibiotic therapy. The presenters also highlighted the ease of use of the system and positive feedback from technicians using the instrument, as well as the value of consumables that can be stored at room temperature.

The study design also includes partnering with the hospitals’ antimicrobial stewardship teams to conduct retrospective chart reviews to determine what actions clinicians may have taken with access to the rapid antibiotic susceptibility test (AST) results. In an early dataset from George Washington University, chart reviews revealed that 44% of patients would have been exposed to fewer antibiotics had the study results been available clinically. Additionally, the rapid AST results would have enabled antibiotic de-escalation in 33% of patients, antibiotic escalation in 22% of patients, and potential reduction in length of stay in 22% of patients.

Next steps for both hospital labs include completing enrollment of patient samples, finalizing retrospective chart reviews, and preparing a manuscript to publish their findings.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar[®], accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Two leading US microbiology labs present interim evaluation data on webinar](#)